Price
No data yet.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $46.72B | $7.81B | $3.20 |
| 2024 | $44.29B | $5.56B | $2.19 |
| 2023 | $41.62B | $5.40B | $2.15 |
| 2022 | $40.56B | $8.37B | $3.19 |
| 2021 | $39.17B | $6.22B | $2.49 |
Social Signal Score
Earnings
Fri, Oct 23(in 2 months)
Consensus estimate $1.72 per share
Typical surprise +4.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$1.21 vs $1.10beat
- Thu, Apr 23$1.10 vs $1.06beat
- Thu, Jan 29$0.89 vs $0.84beat
- Fri, Oct 24$1.70 vs $1.60beat
- Thu, Jul 31$0.90 vs $0.96miss
- Thu, Apr 24$0.94 vs $0.90beat
Estimates and results for SNY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from SNY's reported EPS growth of 6.5% a year over 4 years.
- EPS in 5 years
- $4.39
- Implied price
- $57.01
- Return from $44.13
- 5.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $28.35 — -35.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 9 | 11 | 13 | 15 | 17 |
|---|---|---|---|---|---|
| -3.5% | -11.4% | -7.8% | -4.6% | -1.9% | 0.6% |
| 1.5% | -6.8% | -3.0% | 0.3% | 3.2% | 5.8% |
| 6.5% | -2.2% | 1.8% | 5.3% | 8.3% | 11.1% |
| 11.5% | 2.4% | 6.6% | 10.2% | 13.4% | 16.3% |
| 16.5% | 7.0% | 11.4% | 15.1% | 18.5% | 21.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (1)
- Newsaccessnewswire.com·5h ago·Neutral
AimwellBio Secures Patented Behavioral AI Portfolio Backed by Oxford Science and Sanofi Pilot; Inventor Dr. Chris A. Jones Joins Board of Advisors Executed IP assignment brings a decade of technology, published research, and pharma-tested behavioral engagement capabilities into AimwellBio as the Company expands its scientific and medical advisory network MIAMI, FL / ACCESS Newswire / August 17, 2026 / AimwellBio (OTCID:AIMN) today announced the executed assignment of the Trustr intellectual prop
View source ↗